Limited M1 Disease: A Significant Prognostic Factor for Stage IV Breast Cancer

Purpose

The prognosis of patients with breast cancer presenting with distant metastasis can vary depending on disease extent. This study evaluates a definition of limited M1 disease in association with survival in a cohort of women presenting with metastatic breast cancer.

Methods

The study cohort comprised 692 women referred to the BC Cancer Agency between 1996 and 2005 with M1 breast cancer at presentation. Limited M1 disease was defined as <5 metastatic lesions confined to one anatomic subsite. Extensive M1 disease was defined as ??5 lesions or disease in more than one subsite. Clinicopathologic and treatment characteristics and overall survival (OS) were compared between subjects with limited (n?=?233) versus extensive (n?=?459) M1 disease. Multivariable analysis was performed by Cox regression modeling.

Results

Median follow-up time was 1.9?years. Five-year Kaplan-Meier OS was significantly higher in patients with limited compared to extensive M1 disease (29.7 vs. 13.1?%, p?p?Conclusions Limited M1 disease, defined as <5 metastatic lesions confined to one anatomic subsite, is a relevant favorable prognostic factor in patients with stage IV breast cancer. This definition may be used in conjunction with other clinicopathologic factors to select patients for more aggressive systemic and locoregional treatments.     

The associations between diode laser (810 nm) therapy and chronic wound healing and pain relief: Light into the chronic wound patient's life

Chronic wounds have become one of the major issues in medicine today, the treatments for which include dressing changes, negative pressure wound therapy, hyperbaric oxygen, light irradiation, surgery and so forth. Nevertheless, the application of diode lasers in chronic wounds has rarely been reported. This retrospective cohort study aimed to evaluate the therapeutic effect of diode laser (810 nm) irradiation on chronic wounds. Eighty-nine patients were enrolled in the study. The control group (41 patients) received traditional dressing change therapy, while the diode laser treatment group (48 patients) were patients received additional treatment with diode laser (810 nm) irradiation for 10 min at each dressing change. Wound healing time was compared between two groups, while the pain relief index was creatively introduced to evaluate the effect of relieving wound pain, which was calculated by the difference in pain scores between the first and last dressing changes divided by the number of treatment days. The wound healing time of the diode laser treatment group was 22.71 ± 8.99 days, which was significantly shorter than that of the control group (37.44 ± 23.42 days). The pain relief index of the diode laser treatment group was 0.081 ± 0.055, which was significantly increased compared with that of the control group (0.057 ± 0.033). Our findings suggest that diode laser irradiation has the potential to promote healing in chronic wounds and relieve wound pain.     

Manufacturing Better Outcomes in Cardiovascular Intervention: 3D Printing in Clinical Practice Today

Purpose of review

Describe and evaluate the integration of 3D printing-related innovations into current cardiovascular treatment paradigms and examine the state of regulatory and reimbursement hurdles ahead.

Recent findings

Mounting years of clinical experience have established the utility of printed models of patient anatomy in numerous treatment and teaching scenarios, most notably as pre- and intra-procedural planning tools guiding decision-making for congenital heart disease and catheter-based interventions. In part due to a continued lack of reimbursement and under-defined (and slow to evolve) regulatory status, these use cases remain largely investigational even as they grow increasingly routine. Patients, physicians, and/or imaging centers therefore remain burdened by the associated cost to create such models, and the perceptual and decision-making enhancements, while demonstrable and significant, still may not clearly or independently justify a potentially high cost.Simulation and implantable device applications may represent a deeper well of unrealized value in cardiovascular intervention; however, further development of these applications relies on—and is throttled by—progress in material science and tissue-engineering research. The relevance of simulation applications in recent years is also now in competition with digital analogs including augmented and virtual reality. Innovative incorporation of alternative manufacturing processes such as porous scaffold infusion, injection molding, and vascular mesh forming can provide immediate access to more realistic tissue-mimicking materials and custom implantable devices, while comparable and directly printable materials continue to be developed. Tissue-engineering applications remain years if not decades away from a more substantive role in translatable clinical research. Regulatory challenges associated with in-house manufacture of implantable investigational devices are complex and subject to change, and the success of some in navigating these hurdles in non-cardiovascular applications is instructive and encouraging.

Summary

Complex geometries characterizing cardiovascular anatomy are an ideal use case for translating the perceptual advantages of printed models of patient anatomy into better decision-making, especially so in the setting of congenital or post-surgical anatomy. Procedural planning applications take further advantage of the demonstrably robust dimensional reproduction of patient anatomy, with notably rapid integration into surgical and catheter-based intervention workflows. Despite a continued lack of codification in the healthcare system, 2018 could be a milestone year for 3D printing services, pending a successful application for a CPT Category III designation.

     

A Randomized Prospective Study on Outcomes of an Empathy Intervention among Second-year Student Pharmacists

Objective. To determine the impact of a single, 3-day intervention on empathy levels as measured by the validated Jefferson Scale of Empathy-Health Profession Students version (JSE-HPS).Methods. Forty second-year student pharmacists were recruited to participate in a non-blinded prospective study. Subjects were randomized to an intervention group (n=20) or control group (n=20) and completed the JSE-HPS at baseline, 7 days postintervention, and 90 days postintervention. The intervention group consisted of a 3-day simulation, each day including a designated activity with loss of dominant hand usage, vision, and speech.Results. The 3-day simulation increased empathy levels in the intervention group compared to the control group 7 days postintervention (p=0.035). However, there were no effects on empathy levels 90 days postintervention (p=0.38).Conclusion. Empathy scores increased but were not sustained in the long-term with a 3-day empathy intervention.     

Do Formulation Differences between the Reference Listed Drug and Generic Piperacillin-Tazobactam Impact Reconstitution?

Pharmaceutical differences between the reference listed drug (RLD) and generic formulations of piperacillin-tazobactam may impact the reconstitution process for intravenous administration. This study evaluated the RLD against three generic formulations and measured their reconstitution times using a standardized process. The mean (standard deviation [SD]) reconstitution time for one generic formulation was 5.57 (1.49) min, which was 35% to 42% longer (P < 0.002) than that for the RLD and two other formulations. Observable microscopic differences in powder particle morphology may explain these findings.